Welcome Guest
Home > Clinical Lymphoma Myeloma > Volume 7 |  Issue 4 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Jemal A,Ward E,Siegel R,Murray T : Cancer statistics, 2006 : CA Cancer J Clin : 2006 : .
    2.  Jemal A,Ward E,Siegel R : American Cancer Society: Multiple Myeloma ; 2006 : : : .
    3.  Witzig TE,Kyle RA,Gertz MA : Review of 1027 patients with newly diagnosed multiple myeloma : Mayo Clin Proc : 2003 : .
    4.  Tricot G,Barlogie B,Shaughnessy J : Treatment of multiple myeloma : Blood : 2004 : .
    5.  Tricot G,Barlogie B,Shaughnessy J : New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals : Clin Lymphoma Myeloma : 2005 : .
    6.  Eisenhauer EA,Therasse P,Arbuck SG,Berlin J,Neubauer P,Swanson,WG,Swain SM,Whaley FS,Gerber MC,Jemal A,Ward E,Siegel R,Tricot G,Barlogie B,Shaughnessy J : : : : .
    7.  Durie BG,Wolf J,Jagannath S,Durie BGM,Durie B : Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma : Br J Haematol : 2005 : .
    8.  Rajkumar SV,Vesole D,Blood E : Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group : J Clin Oncol : 2006 : .
    9.  Rajkumar SV,Vesole D,Blood E : Thalidomide and dexamethasone in newly diagnosed multiple myeloma: long-term results in patients not undergoing upfront autologous stem cell transplantation : J Clin Oncol : 2005 : .
    10.  Rajkumar SV,Lacy MQ,Hayman SR : Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma : Blood : 2005 : .
    11.  Giralt S,Weber D,Alexanian R : Impact of complete remission with intensive therapy in patients with responsive multiple myeloma : Bone Marrow Transplant : 2001 : .
    12.  Tricot G,Spencer T,Sawyer J : Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants : Br J Haematol : 2002 : .
    13.  Bladé J,Nadal E,Gine E,Blade J : High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission : Bone Marrow Transplant : 2004 : .
    14.  Davies FE,Forsyth PD,Rawstron,Rawstron AC : The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma : Br J Haematol : 2001 : .
    15.  Lahuerta JJ,Martinez-Lopez J,Serna JD : Remission status defined by immunofixation vs.electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients : Br J Haematol : 2000 : .
    16.  Cavo M,Corradini P,Lokhorst H : Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma : Blood : 2003 : .
    17.  Harousseau JL,Attal M,Facon T : Single versus double autologous stem-cell transplantation for multiple myeloma : N Engl J Med : 2003 : .
    18.  Harousseau JL,Attal M,Stoppa AM : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome : N Engl J Med : 1996 : .
    19.  Suppiah R,Baz R,Almhanna K,Harousseau JL,Attal M,Stoppa AM : Doxil, vincristine, reduced frequency dexamethasone in combination with thalidomide (DVd-T) is associated with higher overall and progression free survival as compared to DVd in patients with multiple myeloma (MM) : Blood : 2005 : .
    20.  Harousseau JL,Attal M,Stoppa AM : A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis : Blood : 2005 : .
    21.  Harousseau JL,Attal M,Stoppa AM : Thalidomide-dexamethasone versus melphalan-prednisone as first line treatment in elderly patients with multiple myeloma: an interim analysis : Haematol J : 2005 : .
    22.  Barlogie B,Kyle RA,Anderson KC : Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III Intergroup trial S9321 [published erratum in J Clin Oncol 2006; 24:2687] : J Clin Oncol : 2006 : .
    23.  Giaccone G,Ludwig H,Khayat D : Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies : Cancer : 2005 : .
    24.  Orlowski RZ,Stinchcombe TE,Mitchell BS : Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies : J Clin Oncol : 2002 : .
    25.  Richardson PG,Berenson J,Barlogie B : A phase 2 study of bortezomib in relapsed, refractory myeloma : N Engl J Med : 2003 : .
    26.  Berenson J,Barlogie B,Jagannath S : A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma : Br J Haematol : 2004 : .
    27.  Richardson PG,Sonneveld P,Schuster MW : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma : N Engl J Med : 2005 : .
    28.  Berenson JR,Yang HH,Sadler K : Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma : J Clin Oncol : 2006 : .
    29.  Berenson JR,Yang HH,Sadler K : Addition of bortezomib (Velcade™) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM) : Blood : 2004 : .
    30.  Barlogie B,Zangari M,Hollmig K,Berenson JR,Yang HH,Sadler K : Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) : Blood : 2004 : .
    31.  Berenson JR,Yang HH,Sadler K : : Blood : 2004 : .
    32.  Berenson JR,Yang HH,Sadler K : A phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM): encouraging preliminary results : Blood : 2004 : .
    33.  Orlowski RZ,Voorhees PM,Garcia RA : Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies : Blood : 2005 : .
    34.  Orlowski RZ,Voorhees PM,Garcia RA : Phase II trial of single agent bortezomib (Velcade) in patients with previously untreated symptomatic multiple myeloma (MM) : Blood : 2004 : .
    35.  Orlowski RZ,Voorhees PM,Garcia RA : Bortezomib plus dexamethasone as induction treatment prior to stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase III study : Clin Adv Hematol Oncol : 2005 : .
    36.  Orlowski RZ,Voorhees PM,Garcia RA : A phase I/II national, multi-center, open-label, study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma (MM) patients : Blood : 2005 : .
    37.  Giralt S,Wang M,Delasalle K,Orlowski RZ,Voorhees PM,Garcia RA : Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy : Blood : 2005 : .
    38.  Oakervee HE,Popat R,Curry N : PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma : Br J Haematol : 2005 : .
    39.  Oakervee HE,Popat R,Curry N : Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB Study 10301 : Clin Adv Hematol Oncol : 2005 : .
    40.  Orlowski RZ,Peterson BL,Sanford B : Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with multiple myeloma: Cancer and Leukemia Group B study 1031 : Blood : 2006 : .
    41.  Nasta SD,Carrum GM,Shahab I,Monconduit M,Le Loet X,Bernard JF,Orlowski RZ,Peterson BL,Sanford B : Effective treatment of advanced multiple myeloma refractory to alkylating agents : N Engl J Med : 1984 : .
    42.  Lokhorst HM,Meuwissen OJ,Bast EJ : VAD chemotherapy for refractory multiple myeloma : Br J Haematol : 1989 : .
    43.  Samson D,Gaminara E,Newland A,Lokhorst HM,Meuwissen OJ,Bast EJ : VAD-based regimens as primary treatment for multiple myeloma : Am J Hematol : 1990 : .
    44.  Lokhorst HM,Meuwissen OJ,Bast EJ : Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide : Oncologist : 2003 : .
    45.  Dimopoulos MA,Zervas K,Pouli A : Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma : Ann Oncol : 2003 : .
    46.  Dimopoulos MA,Zervas K,Pouli A : DVd versus VAd in the treatment of patients with newly diagnosed multiple myeloma: an update from a randomized multicenter trial : Blood : 2003 : .
    47.  Hussein MA,Wood L,Hsi E : A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients : Cancer : 2002 : .
    48.  Rifkin RM,Gregory SA,Mohrbacher A : Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial : Cancer : 2006 : .
    49.  Rifkin RM,Gregory SA,Mohrbacher A : Updated results from a randomized multicenter trial of DVd vs Vad in patients with newly diagnosed multiple myeloma : Proc Am Soc Clin Oncol : 2004 : .
    50.  Rifkin RM,Gregory SA,Mohrbacher A : Pegylated liposomal doxorubicin (PLD), vincristine and reduced-dose dexamethasone (DVd) in the treatment of a predominantly African American population with multiple myeloma : Blood : 2005 : .
    51.  Rifkin RM,Gregory SA,Mohrbacher A : : Blood : 2005 : .
    52.  Offidani M,Corvatta L,Piersantelli MN : Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma : Blood : 2006 : .
    53.  Dimopoulos MA,Zervas K,Hatzicharissi E : Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil): a phase II multicenter study : Ann Oncol : 2004 : .
    54.  Small GW,Shi YY,Edmund NA : Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role : Mol Pharmacol : 2004 : .
    55.  Richardson PG,Mitsiades N,Mitsiades CS : The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications : Blood : 2003 : .
    56.  Small GW,Somasundaram S,Moore DT : Repression of mito-gen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK : J Pharmacol Exp Ther : 2003 : .
    57.  Carmichael J,Alberts DS,Muggia FM : Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials : Semin Oncol : 2004 : .
    58.  Carmichael J,Alberts DS,Muggia FM : Cardiac safety of liposomal anthracyclines : Oncologist : 2003 : .
    59.  Carmichael J,Alberts DS,Muggia FM : Combination therapy with Velcade, Doxil, and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM) : Blood : 2005 : .
    60.  Carmichael J,Alberts DS,Muggia FM : Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma : Blood : 2005 : .
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume Number 7
  •  Issue 4
    • Cover Date: January 01, 2007


Bortezomib in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Multiple Myeloma


Authors: Rami Manochakian, Kena C. Miller, Asher Alban Chanan-Khan

Many novel agents and new combinations (including bortezomib, thalidomide, and lenalidomide) have been developed in recent years for the treatment of multiple myeloma (MM), creating major shifts in therapeutic management. Achieving complete response (CR)/near CR (nCR) generally serves as a reliable clinical surrogate for overall treatment outcome, ie, prolonged survival. Indeed, some newer induction regimens are yielding similar median time to disease progression effects compared with transplantation. Thus, it can be a dilemma whether a patient with CR/nCR needs to be subjected to the potential morbidity associated with transplantation after induction therapy. Combining new agents with chemotherapy-based regimens appears to offer higher overall response and CR/nCR rates than similar combinations that do not include chemotherapy. We review the preclinical and clinical rationale for combining bortezomib with pegylated liposomal doxorubicin for the treatment of MM. The synergistic interaction in sensitizing each other toward myeloma cells in vitro and their complementary in vivo activities have justified clinical studies. We summarize data for completed and ongoing phase I/II trials of this combination. To date, results have been sufficiently encouraging to initiate an international, multicenter, randomized, phase III trial comparing bortezomib with or without pegylated liposomal doxorubicin in patients with relapsed/refractory MM. The results of this trial will confirm whether the rationale for combining bortezomib with pegylated liposomal doxorubicin is validated by improved clinical outcome, ie, improved time to progression, for patients with MM.

Keywords: Antiangiogenesis, Dose-limiting toxicities, Stem cell transplantation


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. Pengeluaran SDY